Skip to main content
EyePoint Pharmaceuticals, Inc. logo

EyePoint Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · EYPT ISIN · US74440J1016 LEI · 549300QE1RU34T50MR69 US Manufacturing
Open in API
Filings indexed 1,019 across all filing types
Latest filing 2011-05-11 Interim / Quarterly Rep…
Country US United States of America
Listing US EYPT

About EyePoint Pharmaceuticals, Inc.

https://eyepointpharma.com/

EyePoint Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for serious retinal diseases. The company leverages its proprietary Durasert E™ technology, a bio-erodible platform for sustained intraocular drug delivery, to create durable therapies. Its lead investigational product, DURAVYU™ (EYP-1901), combines the tyrosine kinase inhibitor vorolanib with the Durasert E™ system for the potential treatment of VEGF-mediated retinal diseases. The company's goal is to improve patient outcomes and reduce treatment burden by providing long-lasting treatments for chronic eye conditions.

Recent filings

Filing Released Lang Actions
FORM 10-Q
Interim / Quarterly Report 9M 2011
2011-05-11 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 10, 2011, reporting the issuance of a press release announcing third quarter fiscal year 2011 results. The text explicitly states that the press release is furnished as an exhibit and that the information is not deemed filed for certain regulatory purposes. The document itself does not contain detailed financial statements or substantive financial data but rather announces the results and provides the press release as an exhibit. The length is 2630 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, such a document is best classified as a Regulatory Filing (RNS) because it is a current report announcing financial results but not the full earnings release or detailed financial report itself.
2011-05-10 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K, which is a current report filed with the SEC to announce unscheduled material events or corporate changes. The text mentions a press release and presentation slides related to a scientific meeting (ARVO Annual Meeting) and new data from a study. The document does not contain comprehensive financial statements or detailed financial analysis. It is primarily an announcement of an event and related materials, not a full financial report or earnings release. The length is 2557 characters, which is relatively short and consistent with a current report. Therefore, the document fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2011-05-03 English
ORBIS INVESTMENT MANAGEMENT
Major Shareholding Notification
2011-02-17 English
Major Shareholding Notification 2011
Major Shareholding Notification
2011-02-14 English
ORBIS INVESTMENT MANAGEMENT (AUSTRALIA) PTY LIMITED
Major Shareholding Notification
2011-02-14 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.